Study of ALTO-101 in Patients With Schizophrenia
← catalyst calendarSponsored by Alto Neuroscience (industry) · ANRO — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
82estimated
Sites
14
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-06-11 | actual | When the study began enrolling |
| Primary completion | Feb 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Mar 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2024-07-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-12-26 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Schizophrenia
- Cognitive Impairment
Interventions
- Drug: ALTO-101
- Device: ALTO-101 Transdermal Delivery System
- Drug: Placebo
- Device: Placebo Transdermal Delivery System
Primary outcome
what the primary-completion date above is the date OFTheta band activity
measured Treatment Period 1 - Day 6 and Day 11; Treatment Period 2 - Day 6 and Day 11
Permalink · ANRO's whole pipeline · Catalyst calendar · Every registered study · What changed